EXO-TARGET
LIVE

Serial Number

90357299

Owner

ILIAS Biologics Inc.

Attorney

Janice Housey

Filing Date

Dec 3, 2020

Add to watchlist:

No watchlists yet
View on USPTO

EXO-TARGET Trademark

Serial Number: 90357299 • Registration: 7637167

EXO-TARGET is a trademark filed by ILIAS Biologics Inc. on December 3, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ILIAS Biologics Inc. (11 trademarks)

40-20 Techno 6-ro, Yuseong-gu
Daejeon 34014 , KR

Entity Type: 03

Trademark Details

Filing Date

December 3, 2020

Registration Date

January 7, 2025

Published for Opposition

November 19, 2024

Goods & Services

Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose

Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations in the nature of comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemical drug delivery agent in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use

Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 16, 2026 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Mar 16, 2026 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 16, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 16, 2026 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 7, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 19, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 19, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 13, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 7, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 8, 2024 GNFN
FINAL REFUSAL E-MAILED
Jul 8, 2024 GNFR
FINAL REFUSAL WRITTEN
Jul 8, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2024 CRFA
ASSIGNED TO LIE
Jun 24, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 26, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 26, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 26, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 26, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 1, 2024 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jul 6, 2023 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 18, 2023 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 12, 2022 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 18, 2022 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 5, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 5, 2022 GNSL
SUSPENSION LETTER WRITTEN
Jan 5, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 3, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 3, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 3, 2021 CNRT
ASSIGNED TO EXAMINER
May 20, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 9, 2021 NWOS
NEW APPLICATION ENTERED
Dec 7, 2020 NWAP